NCT03180918 Male Fertility Preservation Using Cryopreservation of Testicular Tissue Before Highly Gonadotoxic Cancer Treatment
| NCT ID | NCT03180918 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Gumy-Pause Fabienne |
| Condition | Childhood Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2015-01 |
| Primary Completion | 2100-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2015-01 with a primary completion date of 2100-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Background: Due to the remarkable improvement in treatments these last decades, long term survival can be expected in more than 80% of childhood cancer patients. Unfortunately, cancer treatments can be harmful to the gonads and can affect reproductive and endocrine functions. While loss of fertility is a major concern for most patients, sperm cryopreservation should be offered to all pubertal male patients. For prepubertal boys, only the experimental option of testicular biopsy in order to cryopreserve testicular stem cells can be proposed. Primary aims \- To cryopreserve testicular tissue of prepubertal patient receiving highly gonadotoxic oncological treatment. Secondary aims * To cryopreserve testicular tissue after failure of sperm cryopreservation in pubertal patient with high risk of infertility * To create a database in order to record clinical and biological follow-up data * To create a research biobank for future research projects Multicentric study: HUG, CHUV, UKBB
Eligibility Criteria
Inclusion Criteria: * Prepubertal patients aged 3 months and older * Peri and pubertal patients after failure of sperm cryopreservation * Patients presenting high risk of infertility because of gonadotoxic treatments (i.e high dose of alkylating agents, testicular irradiation, total body irradiation). * Multidisciplinary team consensus in favour of proposition to cryopreserve testicular tissue Exclusion Criteria: * Patients under the age of 3 months * Refusal of the patient and/or his parents * Treatments that are not highly gonadotoxic
Contact & Investigator
Fabienne Gumy-Pause, Dr
✉ fabienne.gumypause@hcuge.chFabienne Gumy-Pause
STUDY CHAIR
University Hospital, Geneva
Frequently Asked Questions
Who can join the NCT03180918 clinical trial?
This trial is open to male participants only, aged 3 Months or older, up to 18 Years, studying Childhood Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03180918 currently recruiting?
Yes, NCT03180918 is actively recruiting participants. Contact the research team at fabienne.gumypause@hcuge.ch for enrollment information.
Where is the NCT03180918 trial being conducted?
This trial is being conducted at Basel, Switzerland, Geneva, Switzerland, Lausanne, Switzerland.
Who is sponsoring the NCT03180918 clinical trial?
NCT03180918 is sponsored by Gumy-Pause Fabienne. The principal investigator is Fabienne Gumy-Pause at University Hospital, Geneva. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.